{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:57:18Z","timestamp":1788368238713,"version":"build-2803163510"},"reference-count":151,"publisher":"Bentham Science Publishers Ltd.","issue":"15","funder":[{"DOI":"10.13039\/501100010802","name":"University of Zabol","doi-asserted-by":"publisher","award":["UOZ-GR-9618-5"],"award-info":[{"award-number":["UOZ-GR-9618-5"]}],"id":[{"id":"10.13039\/501100010802","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2020,10,16]]},"abstract":"<jats:sec><jats:title\/><jats:p>Recently, manipulation of gene expression and switching genes on or off highlight the potential of nucleic acid-based therapies (NA-BTs). Alzheimer\u2019s Disease (AD) is a common devastating neurodegenerative disease (NDs) responsible for 60-80% of all cases of dementia and predicted as a main public health concern among aged populations. The aim of this study was to outline the current research in the field of NA-BTs for the treatment of AD disabilities, including strategies to suppress the memory and learning defects, to promote recovery processes, and to reinforce social relationships in these patients. This review was performed via evaluating PubMed reported studies from January 2010 to November 2019. Also, reference lists were checked to find additional studies. All intermediation or complementarity of animal models, case-control and cohort studies, and controlled trials (CTs) on specific NA-BTs to AD were acceptable, although in vitro studies were excluded due to the considerable diversities and heterogeneities. After removing the duplicates according to preferred reporting items for systematic reviews and meta-analyses (PRISMA) instruction, we merged remaining titles across search databases. There are 48 ongoing studies related to the application of nucleic acids in the treatment and diagnosis of AD where more consideration is given to DNA targeting strategies (18 targets for vectors and aptamers), antisense oligonucleotides (10 targets), micro-RNAs mimics (7 targets), antagomiRs (6 targets), small interferences-RNAs (5 targets), as well as mRNAs (2 targets) respectively. All of these targets are grouped into 4 categories according to their role in molecular pathways where amyloid-&amp;#946; (18 targets), neural survival (11 targets), memory and cognition (8 targets), and tau (3 targets) are more targeted pathways, respectively. With recent successes in the systemic delivery of nucleic acids via intravenous injection; it is worth investing in the production of new-generation medicines. There are still several challenges for NA-BTs including, their delivery to the effective modulators, mass production at low cost, sustaining efficacy and minimizing off\u2010target effects. Regarding miRNA-based therapies, given the obvious involvement of miRNAs in numerous facets of brain disease, and the many sophisticated techniques for delivery to the brain, miRNA-based therapies will make new hope for the treatment of neurological diseases such as AD.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389557520666200513122357","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T12:11:25Z","timestamp":1589371885000},"page":"1499-1517","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A Systematic Review of Current Progresses in the Nucleic Acid-Based Therapies for Neurodegeneration with Implications for Alzheimer\u2019s Disease"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1399-1021","authenticated-orcid":true,"given":"Maryam","family":"Ghaffari","sequence":"first","affiliation":[{"name":"Department of Biology, Faculty of Sciences, University of Zabol, Zabol, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4509-5336","authenticated-orcid":true,"given":"Nima","family":"Sanadgol","sequence":"additional","affiliation":[{"name":"Department of Biology, Faculty of Sciences, University of Zabol, Zabol, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0123-1209","authenticated-orcid":true,"given":"Mohammad","family":"Abdollahi","sequence":"additional","affiliation":[{"name":"Toxicology and Diseases Group, Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), and Department of Toxicology and Pharmacology, School of Pharmacy, Tehran University of Medical Sciences, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","author":"Sengoku R.","year":"2019","unstructured":"Sengoku R.; Aging and Alzheimer\u2019s Disease Pathology. Neuropathology 2019","journal-title":"Neuropathology"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s00415-015-7698-3","volume":"262","author":"Palas\u00ed A.","year":"2015","unstructured":"Palas\u00ed A.; Guti\u00e9rrez-Iglesias B.; Alegret M.; Pujadas F.; Olabarrieta M.; Li\u00e9bana D.; Quintana M.; \u00c1lvarez-Sab\u00edn J.; Boada M.; Differentiated clinical presentation of early and late-onset Alzheimer\u2019s disease: Is 65 years of age providing a reliable threshold? J Neurol 2015,262(5),1238-1246","journal-title":"J Neurol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","volume":"12","author":"Dubois B.","year":"2016","unstructured":"Dubois B.; Hampel H.; Feldman H.H.; Scheltens P.; Aisen P.; Andrieu S.; Bakardjian H.; Benali H.; Bertram L.; Blennow K.; Broich K.; Cavedo E.; Crutch S.; Dartigues J.F.; Duyckaerts C.; Epelbaum S.; Frisoni G.B.; Gauthier S.; Genthon R.; Gouw A.A.; Habert M.O.; Holtzman D.M.; Kivipelto M.; Lista S.; Molinuevo J.L.; O\u2019Bryant S.E.; Rabinovici G.D.; Rowe C.; Salloway S.; Schneider L.S.; Sperling R.; Teichmann M.; Carrillo M.C.; Cummings J.; Jack C.R.; Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer\u2019s Association on \u201cThe Preclinical State of AD\u201d; July 23, 2015; Washington DC, USA. Preclinical Alzheimer\u2019s disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement 2016,12(3),292-323","journal-title":"Alzheimers Dement"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"952","DOI":"10.2174\/1567205013666160314150501","volume":"13","author":"Dorszewska J.","year":"2016","unstructured":"Dorszewska J.; Prendecki M.; Oczkowska A.; Dezor M.; Kozubski W.; Molecular Basis of Familial and Sporadic Alzheimer\u2019s Disease. Curr Alzheimer Res 2016,13(9),952-963","journal-title":"Curr Alzheimer Res"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7861\/clinmedicine.16-3-247","volume":"16","author":"Briggs R.","year":"2016","unstructured":"Briggs R.; Kennelly S.P.; O\u2019Neill D.; Drug treatments in Alzheimer\u2019s disease. Clin Med (Lond) 2016,16(3),247-253","journal-title":"Clin Med (Lond)"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cbpa.2018.05.018","volume":"44","author":"Scannevin R.H.","year":"2018","unstructured":"Scannevin R.H.; Therapeutic strategies for targeting neurodegenerative protein misfolding disorders. Curr Opin Chem Biol 2018,44,66-74","journal-title":"Curr Opin Chem Biol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/B978-0-12-802395-2.00022-5","volume":"Vol. 145","author":"Pihlstr\u00f8m L.","year":"2017","unstructured":"Pihlstr\u00f8m L.; Wiethoff S.; Houlden H.; Handbook of Clinical Neurology 2017,Vol. 145,309-323","journal-title":"Handbook of Clinical Neurology"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-12-802810-0.00001-5","author":"Yacoubian T.A.","year":"2017","unstructured":"Yacoubian T.A.; Neurodegenerative Disorders: Why Do We Need New Therapies?Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer\u2019s Disease 2017,1-16","journal-title":"Neurodegenerative Disorders: Why Do We Need New Therapies?Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer\u2019s Disease"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/164_2017_60","volume":"Vol. 245","author":"Longhena F.","year":"2018","unstructured":"Longhena F.; Spano P.F.; Bellucci A.; Handbook of Experimental Pharmacology 2018,Vol. 245,85-110","journal-title":"Handbook of Experimental Pharmacology"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s12603-014-0515-3","volume":"19","author":"Lista S.","year":"2015","unstructured":"Lista S.; Dubois B.; Hampel H.; Paths to Alzheimer\u2019s disease prevention: from modifiable risk factors to biomarker enrichment strategies. J Nutr Health Aging 2015,19(2),154-163","journal-title":"J Nutr Health Aging"},{"key":"ref=11","first-page":"329","author":"De-Paula V.J.","year":"2012","unstructured":"De-Paula V.J.; Radanovic M.; Diniz B.S.; Forlenza O.V.; Alzheimer\u2019s Disease 2012,329-352","journal-title":"Alzheimer\u2019s Disease"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.neuron.2005.10.028","volume":"48","author":"Cirrito J.R.","year":"2005","unstructured":"Cirrito J.R.; Yamada K.A.; Finn M.B.; Sloviter R.S.; Bales K.R.; May P.C.; Schoepp D.D.; Paul S.M.; Mennerick S.; Holtzman D.M.; Synaptic activity regulates interstitial fluid amyloid-\u03b2 levels in vivo. Neuron 2005,48(6),913-922","journal-title":"Neuron"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40035-018-0107-y","volume":"7","author":"Du X.","year":"2018","unstructured":"Du X.; Wang X.; Geng M.; Alzheimer\u2019s disease hypothesis and related therapies. Transl Neurodegener 2018,7,2","journal-title":"Transl Neurodegener"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.21037\/atm.2018.04.41","volume":"6","author":"Angelopoulou E.","year":"2018","unstructured":"Angelopoulou E.; Piperi C.; DPP-4 inhibitors: A promising therapeutic approach against Alzheimer\u2019s disease. Ann Transl Med 2018,6(12),255","journal-title":"Ann Transl Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.2174\/1567205015666180801111033","volume":"15","author":"Manocha G.","year":"2018","unstructured":"Manocha G.; Ghatak A.; Puig K.; Combs C.; Anti-\u03b14\u03b21 Integrin Antibodies Attenuated Brain Inflammatory Changes in a Mouse Model of Alzheimer\u2019s Disease. Curr Alzheimer Res 2018,15(12),1123-1135","journal-title":"Curr Alzheimer Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.3233\/JAD-160701","volume":"55","author":"Cebers G.","year":"2017","unstructured":"Cebers G.; Alexander R.C.; Haeberlein S.B.; Han D.; Goldwater R.; Ereshefsky L.; Olsson T.; Ye N.; Rosen L.; Russell M.; Maltby J.; Eketj\u00e4ll S.; Kugler A.R.; AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer\u2019s Disease. J Alzheimers Dis 2017,55(3),1039-1053","journal-title":"J Alzheimers Dis"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/jcph.950","volume":"57","author":"Sakamoto K.","year":"2017","unstructured":"Sakamoto K.; Matsuki S.; Matsuguma K.; Yoshihara T.; Uchida N.; Azuma F.; Russell M.; Hughes G.; Haeberlein S.B.; Alexander R.C.; Eketj\u00e4ll S.; Kugler A.R.; BACE1 inhibitor lanabecestat (AZD3293) in a phase 1 study of healthy japanese subjects: Pharmacokinetics and effects on plasma and cerebrospinal fluid A\u03b2 peptides. J Clin Pharmacol 2017,57(11),1460-1471","journal-title":"J Clin Pharmacol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/nan.12378","volume":"43","author":"Zetterberg H.","year":"2017","unstructured":"Zetterberg H.; Review: Tau in biofluids - relation to pathology, imaging and clinical features. Neuropathol Appl Neurobiol 2017,43(3),194-199","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"338ra66","DOI":"10.1126\/scitranslmed.aaf2362","volume":"8","author":"Brier M.R.","year":"2016","unstructured":"Brier M.R.; Gordon B.; Friedrichsen K.; McCarthy J.; Stern A.; Christensen J.; Owen C.; Aldea P.; Su Y.; Hassenstab J.; Tau and A\u03b2 imaging, csf measures, and cognition in alzheimer\u2019s disease. Sci Transl Med 2016,8,338ra66-338ra66","journal-title":"Sci Transl Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s10571-017-0574-1","volume":"38","author":"Chong F.P.","year":"2018","unstructured":"Chong F.P.; Ng K.Y.; Koh R.Y.; Chye S.M.; Tau proteins and tauopathies in alzheimer\u2019s disease. Cell Mol Neurobiol 2018,38(5),965-980","journal-title":"Cell Mol Neurobiol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejmech.2017.07.070","volume":"139","author":"Jouanne M.","year":"2017","unstructured":"Jouanne M.; Rault S.; Voisin-Chiret A-S.S.; Tau protein aggregation in Alzheimer\u2019s disease: An attractive target for the development of novel therapeutic agents. Eur J Med Chem 2017,139,153-167","journal-title":"Eur J Med Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","volume":"14","author":"Congdon E.E.","year":"2018","unstructured":"Congdon E.E.; Sigurdsson E.M.; Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol 2018,14(7),399-415","journal-title":"Nat Rev Neurol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1517\/14728222.2014.870156","volume":"18","author":"Iqbal K.","year":"2014","unstructured":"Iqbal K.; Gong C-X.; Liu F.; Microtubule-associated protein tau as a therapeutic target in Alzheimer\u2019s disease. Expert Opin Ther Targets 2014,18(3),307-318","journal-title":"Expert Opin Ther Targets"},{"key":"ref=24","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aaf7580","volume":"9","author":"Prabakaran S.","year":"2016","unstructured":"Prabakaran S.; Gough N.R.; PP2A to Alzheimer\u2019s rescue. Sci Signal 2016,9","journal-title":"Sci Signal"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/alzrt277","volume":"6","author":"Kontsekova E.","year":"2014","unstructured":"Kontsekova E.; Zilka N.; Kovacech B.; Skrabana R.; Novak M.; Identification of structural determinants on tau protein essential for its pathological function: Novel therapeutic target for tau immunotherapy in Alzheimer\u2019s disease. Alzheimers Res Ther 2014,6(4),45","journal-title":"Alzheimers Res Ther"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s00702-010-0438-z","volume":"117","author":"Heneka M.T.","year":"2010","unstructured":"Heneka M.T.; O\u2019Banion M.K.; Terwel D.; Kummer M.P.; Neuroinflammatory processes in Alzheimer\u2019s disease. J Neural Transm (Vienna) 2010,117(8),919-947","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2016.07.003","volume":"61","author":"Spangenberg E.E.","year":"2017","unstructured":"Spangenberg E.E.; Green K.N.; Inflammation in Alzheimer\u2019s disease: Lessons learned from microglia-depletion models. Brain Behav Immun 2017,61,1-11","journal-title":"Brain Behav Immun"},{"key":"ref=28","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/480739","volume":"2013,","author":"Ramesh G.","year":"2013","unstructured":"Ramesh G.; MacLean A.G.; Philipp M.T.; Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflamm 2013,2013,","journal-title":"Mediators Inflamm"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1515\/bmc-2016-0029","volume":"8","author":"Bol\u00f3s M.","year":"2017","unstructured":"Bol\u00f3s M.; Perea J.R.; Avila J.; Alzheimer\u2019s disease as an inflammatory disease. Biomol Concepts 2017,8(1),37-43","journal-title":"Biomol Concepts"},{"key":"ref=30","author":"Chen J.","year":"2017","unstructured":"Chen J.; Sun Z.; Jin M.; Tu Y.; Wang S. X.Y.-J.; of; 2017, U. AGEs\/RAGE\/Rho\/ROCK Pathway inhibition suppresses nonspecific neuroinflammation by regulating BV2 microglial M1\/M2 Polarization through the NF- \u039aB pathway jingkao chen. jnijournal com 2017","journal-title":"jnijournal com"},{"key":"ref=31","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2017.00227","volume":"9","author":"Hirbec H., E.","year":"2017","unstructured":"Hirbec H., E.; Noristani H.N.; Perrin F.E.; Microglia responses in acute and chronic neurological diseases: What microglia-specific transcriptomic studies taught (and Did Not Teach) Us. Front Aging Neurosci 2017,9","journal-title":"Front Aging Neurosci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"624.e11","DOI":"10.1016\/j.neurobiolaging.2011.03.004","volume":"33","author":"Saresella M.","year":"2012","unstructured":"Saresella M.; Calabrese E.; Marventano I.; Piancone F.; Gatti A.; Farina E.; Alberoni M.; Clerici M.; A potential role for the PD1\/PD-L1 pathway in the neuroinflammation of Alzheimer\u2019s disease. Neurobiol Aging 2012,33(3),624.e11-624.e22","journal-title":"Neurobiol Aging"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3233\/JAD-2010-091696","volume":"21","author":"Saresella M.","year":"2010","unstructured":"Saresella M.; Calabrese E.; Marventano I.; Piancone F.; Gatti A.; Calvo M.G.; Nemni R.; Clerici M.; PD1 negative and PD1 positive CD4+ T regulatory cells in mild cognitive impairment and Alzheimer\u2019s disease. J Alzheimers Dis 2010,21(3),927-938","journal-title":"J Alzheimers Dis"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nm.4022","volume":"22","author":"Baruch K.","year":"2016","unstructured":"Baruch K.; Deczkowska A.; Rosenzweig N.; Tsitsou-Kampeli A.; Sharif A.M.; Matcovitch-Natan O.; Kertser A.; David E.; Amit I.; Schwartz M.; PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer\u2019s disease. Nat Med 2016,22(2),135-137","journal-title":"Nat Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2174\/1871527315999160111160143","volume":"15","author":"Zhao L.","year":"2016","unstructured":"Zhao L.; Zhao Q.; Zhou Y.; Zhao Y.; Wan Q.; Atorvastatin may correct dyslipidemia in adult patients at risk for alzheimer\u2019s disease through an anti-inflammatory pathway. CNS Neurol Disord Drug Targets 2016,15(1),80-85","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1017\/S104161021600079X","volume":"28","author":"Berk M.","year":"2016","unstructured":"Berk M.; Woods R.L.; Nelson M.R.; Shah R.C.; Reid C.M.; Storey E.; Fitzgerald S.M.; Lockery J.E.; Wolfe R.; Mohebbi M.; Murray A.M.; Kirpach B.; Grimm R.; McNeil J.J.; ASPREE-D: Aspirin for the prevention of depression in the elderly. Int Psychogeriatr 2016,28(10),1741-1748","journal-title":"Int Psychogeriatr"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s40261-017-0549-5","volume":"37","author":"Brazier D.","year":"2017","unstructured":"Brazier D.; Perry R.; Keane J.; Barrett K.; Elmaleh D.R.; pharmacokinetics of cromolyn and ibuprofen in healthy elderly volunteers. Clin Drug Investig 2017,37(11),1025-1034","journal-title":"Clin Drug Investig"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-016-0779-0","volume":"14","author":"Moussa C.","year":"2017","unstructured":"Moussa C.; Hebron M.; Huang X.; Ahn J.; Rissman R.A.; Aisen P.S.; Turner R.S.; Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer\u2019s disease. J Neuroinflammation 2017,14(1),1","journal-title":"J Neuroinflammation"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.biopha.2017.05.060","volume":"92","author":"Huang W.","year":"2017","unstructured":"Huang W.; Li Z.; Zhao L.; Zhao W.; Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer\u2019s disease via modulating the expression of miR-106b. Biomed Pharmacother 2017,92,46-57","journal-title":"Biomed Pharmacother"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/bph.13699","volume":"174","author":"Webster S.P.","year":"2017","unstructured":"Webster S.P.; McBride A.; Binnie M.; Sooy K.; Seckl J.R.; Andrew R.; Pallin T.D.; Hunt H.J.; Perrior T.R.; Ruffles V.S.; Ketelbey J.W.; Boyd A.; Walker B.R.; Selection and early clinical evaluation of the brain-penetrant 11\u03b2-hydroxysteroid dehydrogenase type 1 (11\u03b2-HSD1) inhibitor UE2343 (Xanamem\u2122). Br J Pharmacol 2017,174(5),396-408","journal-title":"Br J Pharmacol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3233\/JAD-132690","volume":"41","author":"Tan C.C.","year":"2014","unstructured":"Tan C.C.; Yu J.T.; Wang H.F.; Tan M.S.; Meng X.F.; Wang C.; Jiang T.; Zhu X.C.; Tan L.; Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer\u2019s disease: A systematic review and meta-analysis. J Alzheimers Dis 2014,41(2),615-631","journal-title":"J Alzheimers Dis"},{"key":"ref=42","first-page":"2944","volume":"8","author":"Shao Z-Q.","year":"2015","unstructured":"Shao Z-Q.; Comparison of the efficacy of four cholinesterase inhibitors in combination with memantine for the treatment of Alzheimer\u2019s disease. Int J Clin Exp Med 2015,8(2),2944-2948","journal-title":"Int J Clin Exp Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.redox.2017.10.014","volume":"14","author":"Cheignon C.","year":"2018","unstructured":"Cheignon C.; Tomas M.; Bonnefont-Rousselot D.; Faller P.; Hureau C.; Collin F.; Oxidative stress and the amyloid beta peptide in Alzheimer\u2019s disease. Redox Biol 2018,14,450-464","journal-title":"Redox Biol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/prca.200780024","volume":"2","author":"Sultana R.","year":"2008","unstructured":"Sultana R.; Butterfield D.A.; Redox proteomics studies of in vivo amyloid beta-peptide animal models of Alzheimer\u2019s disease: Insight into the role of oxidative stress. Proteomics Clin Appl 2008,2(5),685-696","journal-title":"Proteomics Clin Appl"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.freeradbiomed.2007.05.037","volume":"43","author":"Butterfield D.A.","year":"2007","unstructured":"Butterfield D.A.; Reed T.; Newman S.F.; Sultana R.; Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer\u2019s disease and mild cognitive impairment. Free Radic Biol Med 2007,43(5),658-677","journal-title":"Free Radic Biol Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2174\/0929866043407101","volume":"11","author":"Gibson G.L.","year":"2004","unstructured":"Gibson G.L.; Allsop D.; Austen B.M.; Induction of cellular oxidative stress by the beta-amyloid peptide involved in Alzheimer\u2019s disease. Protein Pept Lett 2004,11(3),257-270","journal-title":"Protein Pept Lett"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/j.1471-4159.2005.03647.x","volume":"96","author":"Mohmmad Abdul H.","year":"2006","unstructured":"Mohmmad Abdul H.; Sultana R.; Keller J.N.; St. Clair D.K.; Markesbery W.R.; Butterfield D.A.; Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid \u03b2-Peptide (1-42), H2O2 and kainic acid: Implications for A. J Neurochem 2006,96,1322-1335","journal-title":"J Neurochem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3233\/JAD-2002-4309","volume":"4","author":"Butterfield D.A.","year":"2002","unstructured":"Butterfield D.A.; Griffin S.; Munch G.; Pasinetti G.M.; Amyloid \u03b2-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer\u2019s disease brain exists. J Alzheimers Dis 2002,4(3),193-201","journal-title":"J Alzheimers Dis"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/S0891-5849(02)00794-3","volume":"32","author":"Butterfield D.A.","year":"2002","unstructured":"Butterfield D.A.; Lauderback C.M.; Lipid peroxidation and protein oxidation in Alzheimer\u2019s disease brain: potential causes and consequences involving amyloid \u03b2-peptide-associated free radical oxidative stress. Free Radic Biol Med 2002,32(11),1050-1060","journal-title":"Free Radic Biol Med"},{"key":"ref=50","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/427318","volume":"2014,","author":"Persson T.","year":"2014","unstructured":"Persson T.; Popescu B.O.; Cedazo-Minguez A.; Oxidative stress in Alzheimer\u2019s disease: Why did antioxidant therapy fail? Oxid Med Cell Longev 2014,2014,","journal-title":"Oxid Med Cell Longev"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.2174\/1871523011320240001","volume":"20","author":"Teixeira J.","year":"2013","unstructured":"Teixeira J.; Silva T.; Andrade P.B.; Borges F.; Alzheimer\u2019s disease and antioxidant therapy: How long how far? Curr Med Chem 2013,20(24),2939-2952","journal-title":"Curr Med Chem"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1007\/s11095-017-2199-y","volume":"34","author":"Markowicz-Piasecka M.","year":"2017","unstructured":"Markowicz-Piasecka M.; Sikora J.; Szyd\u0142owska A.; Skupie\u0144 A.; Mikiciuk-Olasik E.; Huttunen K.M.; Metformin - a Future Therapy for Neurodegenerative Diseases : Theme: Drug Discovery, Development and Delivery in Alzheimer\u2019s Disease Guest Editor: Davide Brambilla. Pharm Res 2017,34(12),2614-2627","journal-title":"Pharm Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12951-016-0227-4","volume":"15","author":"Amin F.U.","year":"2017","unstructured":"Amin F.U.; Shah S.A.; Badshah H.; Khan M.; Kim M.O.; Anthocyanins encapsulated by PLGA@PEG nanoparticles potentially improved its free radical scavenging capabilities via p38\/JNK pathway against A\u03b21-42-induced oxidative stress. J Nanobiotechnology 2017,15(1),12","journal-title":"J Nanobiotechnology"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/10286020.2015.1099524","volume":"18","author":"Zhao C.Y.","year":"2016","unstructured":"Zhao C.Y.; Lei H.; Zhang Y.; Li L.; Xu S.F.; Cai J.; Li P.P.; Wang L.; Wang X.L.; Peng Y.; L-3-n-Butylphthalide attenuates neuroinflammatory responses by downregulating JNK activation and upregulating Heme oxygenase-1 in lipopolysaccharide-treated mice. J Asian Nat Prod Res 2016,18(3),289-302","journal-title":"J Asian Nat Prod Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3389\/fnbeh.2015.00347","volume":"9","author":"Sanchez-Mut J.V.","year":"2015","unstructured":"Sanchez-Mut J.V.; Gr\u00e4ff J.; Epigenetic alterations in Alzheimer\u2019s disease. Front Behav Neurosci 2015,9,347","journal-title":"Front Behav Neurosci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev-publhealth-040218-043758","volume":"40","author":"James B.D.","year":"2019","unstructured":"James B.D.; Bennett D.A.; Causes and patterns of dementia: An update in the era of redefining Alzheimer\u2019s Disease. Annu Rev Public Health 2019,40,65-84","journal-title":"Annu Rev Public Health"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/ijms17020189","volume":"17","author":"Kovacs G.G.","year":"2016","unstructured":"Kovacs G.G.; Molecular pathological classification of neurodegenerative diseases: Turning towards precision medicine. Int J Mol Sci 2016,17(2),17","journal-title":"Int J Mol Sci"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1084\/jem.20121274","volume":"209","author":"Kim J.","year":"2012","unstructured":"Kim J.; Eltorai A.E.M.; Jiang H.; Liao F.; Verghese P.B.; Kim J.; Stewart F.R.; Basak J.M.; Holtzman D.M.; Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of A\u03b2 amyloidosis. J Exp Med 2012,209(12),2149-2156","journal-title":"J Exp Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0646-14.2014","volume":"34","author":"Liao F.","year":"2014","unstructured":"Liao F.; Hori Y.; Hudry E.; Bauer A.Q.; Jiang H.; Mahan T.E.; Lefton K.B.; Zhang T.J.; Dearborn J.T.; Kim J.; Culver J.P.; Betensky R.; Wozniak D.F.; Hyman B.T.; Holtzman D.M.; Anti-ApoE antibody given after plaque onset decreases A\u03b2 accumulation and improves brain function in a mouse model of A\u03b2 amyloidosis. J Neurosci 2014,34(21),7281-7292","journal-title":"J Neurosci"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"18007","DOI":"10.1523\/JNEUROSCI.3773-11.2011","volume":"31","author":"Kim J.","year":"2011","unstructured":"Kim J.; Jiang H.; Park S.; Eltorai A.E.M.; Stewart F.R.; Yoon H.; Basak J.M.; Finn M.B.; Holtzman D.M.; Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-\u03b2 amyloidosis. J Neurosci 2011,31(49),18007-18012","journal-title":"J Neurosci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.neuron.2009.11.013","volume":"64","author":"Kim J.","year":"2009","unstructured":"Kim J.; Castellano J.M.; Jiang H.; Basak J.M.; Parsadanian M.; Pham V.; Mason S.M.; Paul S.M.; Holtzman D.M.; Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A \u03b2 clearance. Neuron 2009,64(5),632-644","journal-title":"Neuron"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.18632\/oncotarget.2751","volume":"6","author":"Stefanova N.A.","year":"2015","unstructured":"Stefanova N.A.; Muraleva N.A.; Korbolina E.E.; Kiseleva E.; Maksimova K.Y.; Kolosova N.G.; Amyloid accumulation is a late event in sporadic Alzheimer\u2019s disease-like pathology in nontransgenic rats. Oncotarget 2015,6(3),1396-1413","journal-title":"Oncotarget"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"89ra57","DOI":"10.1126\/scitranslmed.3002156","volume":"3","author":"Castellano J.M.","year":"2011","unstructured":"Castellano J.M.; Kim J.; Stewart F.R.; Jiang H.; DeMattos R.B.; Patterson B.W.; Fagan A.M.; Morris J.C.; Mawuenyega K.G.; Cruchaga C.; Goate A.M.; Bales K.R.; Paul S.M.; Bateman R.J.; Holtzman D.M.; Human ApoE isoforms differentially regulate brain amyloid-\u03b2 peptide clearance. Sci Transl Med 2011,3,89ra57-89ra57","journal-title":"Sci Transl Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fncel.2015.00124","volume":"9","author":"Chin-Chan M.","year":"2015","unstructured":"Chin-Chan M.; Navarro-Yepes J.; Quintanilla-Vega B.; Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci 2015,9,124","journal-title":"Front Cell Neurosci"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2174\/1567205012666150204121719","volume":"12","author":"Yegambaram M.","year":"2015","unstructured":"Yegambaram M.; Manivannan B.; Beach T.G.; Halden R.U.; Role of environmental contaminants in the etiology of Alzheimer\u2019s disease: A review. Curr Alzheimer Res 2015,12(2),116-146","journal-title":"Curr Alzheimer Res"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/j.jmb.2019.01.018","volume":"431","author":"Huat T.J.","year":"2019","unstructured":"Huat T.J.; Camats-Perna J.; Newcombe E.A.; Valmas N.; Kitazawa M.; Medeiros R.; Metal toxicity links to Alzheimer\u2019s disease and neuroinflammation. J Mol Biol 2019,431(9),1843-1868","journal-title":"J Mol Biol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13148-017-0365-z","volume":"9","author":"Delgado-Morales R.","year":"2017","unstructured":"Delgado-Morales R.; Ag\u00eds-Balboa R.C.; Esteller M.; Berdasco M.; Epigenetic mechanisms during ageing and neurogenesis as novel therapeutic avenues in human brain disorders. Clin Epigenetics 2017,9,67","journal-title":"Clin Epigenetics"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1517\/17460441.2014.930124","volume":"Vol. 9","author":"Cacabelos R.","year":"2014","unstructured":"Cacabelos R.; Torrellas C.; Epigenetic drug discovery for alzheimer\u2019s diseaseExpert Opinion on Drug Discovery 2014,Vol. 9,1059-1086","journal-title":"Epigenetic drug discovery for alzheimer\u2019s diseaseExpert Opinion on Drug Discovery"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/ijms19051315","volume":"19","author":"Cui D.","year":"2018","unstructured":"Cui D.; Xu X.; DNA Methyltransferases, DNA Methylation, and Age-Associated cognitive function. Int J Mol Sci 2018,19(5),19","journal-title":"Int J Mol Sci"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2217\/nmt-2018-0004","volume":"8","author":"Stoccoro A.","year":"2018","unstructured":"Stoccoro A.; Copped\u00e8 F.; Role of epigenetics in Alzheimer\u2019s disease pathogenesis. Neurodegener Dis Manag 2018,8(3),181-193","journal-title":"Neurodegener Dis Manag"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3233\/JAD-161104","volume":"61","author":"Chatterjee P.","year":"2018","unstructured":"Chatterjee P.; Roy D.; Rathi N.; epigenetic drug repositioning for alzheimer\u2019s disease based on epigenetic targets in human interactome. J Alzheimers Dis 2018,61(1),53-65","journal-title":"J Alzheimers Dis"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.7150\/thno.21529","volume":"7","author":"Chakravarthy M.","year":"2017","unstructured":"Chakravarthy M.; Chen S.; Dodd P.R.; Veedu R.N.; nucleic acid-based theranostics for tackling alzheimer\u2019s disease. Theranostics 2017,7(16),3933-3947","journal-title":"Theranostics"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"Fire A.","year":"1998","unstructured":"Fire A.; Xu S.; Montgomery M.K.; Kostas S.A.; Driver S.E.; Mello C.C.; Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998,391(6669),806-811","journal-title":"Nature"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/ng.2965","volume":"46","author":"Fort A.","year":"2014","unstructured":"Fort A.; Hashimoto K.; Yamada D.; Salimullah M.; Keya C.A.; Saxena A.; Bonetti A.; Voineagu I.; Bertin N.; Kratz A.; Noro Y.; Wong C.H.; de Hoon M.; Andersson R.; Sandelin A.; Suzuki H.; Wei C.L.; Koseki H.; Hasegawa Y.; Forrest A.R.R.; Carninci P.; Deep transcriptome profiling of mammalian stem cells supports a regulatory role for retrotransposons in pluripotency maintenance. Nat Genet FANTOM Consortium2014,46(6),558-566","journal-title":"Nat Genet"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nature09190","volume":"466","author":"Kapranov P.","year":"2010","unstructured":"Kapranov P.; Ozsolak F.; Kim S.W.S.; Nature - 2010 New Class of Gene-Termini-Associated Human RNAs Suggests a Novel RNA Copying Mechanism.Pdf. naturecom 2010,466,642-646","journal-title":"naturecom"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/ng.368","volume":"41","author":"Faulkner G.J.","year":"2009","unstructured":"Faulkner G.J.; Kimura Y.; Daub C.O.; Wani S.; Plessy C.; Irvine K.M.; Schroder K.; Cloonan N.; Steptoe A.L.; Lassmann T.; Waki K.; Hornig N.; Arakawa T.; Takahashi H.; Kawai J.; Forrest A.R.R.; Suzuki H.; Hayashizaki Y.; Hume D.A.; Orlando V.; Grimmond S.M.; Carninci P.; The regulated retrotransposon transcriptome of mammalian cells. Nat Genet 2009,41(5),563-571","journal-title":"Nat Genet"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1126\/science.1112009","volume":"309","author":"Katayama S.","year":"2005","unstructured":"Katayama S.; Tomaru Y.; Kasukawa T.; Waki K.; Nakanishi M.; Nakamura M.; Nishida H.; Yap C.C.; Suzuki M.; Kawai J.; Suzuki H.; Carninci P.; Hayashizaki Y.; Wells C.; Frith M.; Ravasi T.; Pang K.C.; Hallinan J.; Mattick J.; Hume D.A.; Lipovich L.; Batalov S.; Engstrom P.G.; Mizuno Y.; Faghihi M.A.; Sandelin A.; Chalk A.M.; Mottagui-Tabar S.; Liang Z.; Lenhard B.; Wahlestedt C.; antisense transcription in the mammalian transcriptome. Science (80-) 2005,309,1564-1566","journal-title":"Science (80-)"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1101\/gr.132159.111","volume":"22","author":"Derrien T.","year":"2012","unstructured":"Derrien T.; Johnson R.; Bussotti G.; Tanzer A.; Djebali S.; Tilgner H.; Guernec G.; Martin D.; Merkel A.; Knowles D.G.; Lagarde J.; Veeravalli L.; Ruan X.; Ruan Y.; Lassmann T.; Carninci P.; Brown J.B.; Lipovich L.; Gonzalez J.M.; Thomas M.; Davis C.A.; Shiekhattar R.; Gingeras T.R.; Hubbard T.J.; Notredame C.; Harrow J.; Guig\u00f3 R.; The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 2012,22(9),1775-1789","journal-title":"Genome Res"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nbt.1807","volume":"29","author":"Alvarez-Erviti L.","year":"2011","unstructured":"Alvarez-Erviti L.; Seow Y.; Yin H.; Betts C.; Lakhal S.; Wood M.J.A.; Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011,29(4),341-345","journal-title":"Nat Biotechnol"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0002-9394(02)01327-2","volume":"133","author":"Hutcherson S.L.","year":"2002","unstructured":"Hutcherson S.L.; Lanz R.; A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol Vitravene Study Group2002,133(4),467-474","journal-title":"Am J Ophthalmol"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/01.ieb.0000209784.62228.22","volume":"7","author":"Baumal C.","year":"2006","unstructured":"Baumal C.; A Phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Evidence-Based Ophthalmol [Commentary].2006,7,69-70","journal-title":"Evidence-Based Ophthalmol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.24555","volume":"79","author":"Mendell J.R.","year":"2016","unstructured":"Mendell J.R.; Goemans N.; Lowes L.P.; Alfano L.N.; Berry K.; Shao J.; Kaye E.M.; Mercuri E.; Eteplirsen study group and telethon foundation dmd italian network. longitudinal effect of eteplirsen versus historical control on ambulation in duchenne muscular dystrophy. Ann Neurol 2016,79(2),257-271","journal-title":"Ann Neurol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1365-2125.2012.04469.x","volume":"76","author":"Crooke S.T.","year":"2013","unstructured":"Crooke S.T.; Geary R.S.; Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol 2013,76(2),269-276","journal-title":"Br J Clin Pharmacol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1567205013666161108110031","volume":"13","author":"Perche F.","year":"2016","unstructured":"Perche F.; Uchida S.; Akiba H.; Lin C-Y.; Ikegami M.; Dirisala A.; Nakashima T.; Itaka K.; Tsumoto K.; Kataoka K.; Improved Brain Expression of Anti-Amyloid \u03b2 ScFv by Complexation of MRNA Including a Secretion Sequence with PEG-Based Block Catiomer. Curr Alzheimer Res 2016,13,1-1","journal-title":"Curr Alzheimer Res"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jconrel.2016.06.001","volume":"235","author":"Lin C.Y.","year":"2016","unstructured":"Lin C.Y.; Perche F.; Ikegami M.; Uchida S.; Kataoka K.; Itaka K.; Messenger RNA-based therapeutics for brain diseases: An animal study for augmenting clearance of beta-amyloid by intracerebral administration of neprilysin mRNA loaded in polyplex nanomicelles. J Control Release 2016,235,268-275","journal-title":"J Control Release"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.bbrc.2016.09.119","volume":"479","author":"Kurita H.","year":"2016","unstructured":"Kurita H.; Okuda R.; Yokoo K.; Inden M.; Hozumi I.; Protective roles of SLC30A3 against endoplasmic reticulum stress via ERK1\/2 activation. Biochem Biophys Res Commun 2016,479(4),853-859","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"Geary R.S.","year":"2015","unstructured":"Geary R.S.; Norris D.; Yu R.; Bennett C.F.; Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 2015,87,46-51","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.addr.2015.03.008","volume":"87","author":"Evers M.M.","year":"2015","unstructured":"Evers M.M.; Toonen L.J.A.; van Roon-Mom W.M.C.; Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev 2015,87,90-103","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"Bennett C.F.","year":"2010","unstructured":"Bennett C.F.; Swayze E.E.; RNA targeting therapeutics: Molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010,50,259-293","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","volume":"12","author":"Miller T.M.","year":"2013","unstructured":"Miller T.M.; Pestronk A.; David W.; Rothstein J.; Simpson E.; Appel S.H.; Andres P.L.; Mahoney K.; Allred P.; Alexander K.; Ostrow L.W.; Schoenfeld D.; Macklin E.A.; Norris D.A.; Manousakis G.; Crisp M.; Smith R.; Bennett C.F.; Bishop K.M.; Cudkowicz M.E.; An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 2013,12(5),435-442","journal-title":"Lancet Neurol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.neuron.2017.11.014","volume":"96","author":"Huynh T.V.","year":"2017","unstructured":"Huynh T.V.; Liao F.; Francis C.M.; Robinson G.O.; Serrano J.R.; Jiang H.; Roh J.; Finn M.B.; Sullivan P.M.; Esparza T.J.; Stewart F.R.; Mahan T.E.; Ulrich J.D.; Cole T.; Holtzman D.M.; Age-Dependent effects of apoe reduction using antisense oligonucleotides in a model of \u03b2-amyloidosis. Neuron 2017,96(5),1013-1023.e4","journal-title":"Neuron"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1126\/scitranslmed.aag0481","volume":"9","author":"DeVos S.L.","year":"2017","unstructured":"DeVos S.L.; Miller R.L.; Schoch K.M.; Holmes B.B.; Kebodeaux C.S.; Wegener A.J.; Chen G.; Shen T.; Tran H.; Nichols B.; Zanardi T.A.; Kordasiewicz H.B.; Swayze E.E.; Bennett C.F.; Diamond M.I.; Miller T.M.; Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med 2017,9(374),9","journal-title":"Sci Transl Med"},{"key":"ref=93","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.30","volume":"3,","author":"Sud R.","year":"2014","unstructured":"Sud R.; Geller E.T.; Schellenberg G.D.; Antisense-mediated exon skipping decreases tau protein expression: A potential therapy for tauopathies. Mol Ther Nucleic Acids 2014,3,","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1002\/acn3.657","volume":"5","author":"Self W.K.","year":"2018","unstructured":"Self W.K.; Schoch K.M.; Alex J.; Barth\u00e9lemy N.; Bollinger J.G.; Sato C.; Cole T.; Kordasiewicz H.B.; Swayze E.; Bateman R.J.; Miller T.M.; Protein production is an early biomarker for RNA-targeted therapies. Ann Clin Transl Neurol 2018,5(12),1492-1504","journal-title":"Ann Clin Transl Neurol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"328","DOI":"10.15252\/emmm.201505846","volume":"8","author":"Hinrich A.J.","year":"2016","unstructured":"Hinrich A.J.; Jodelka F.M.; Chang J.L.; Brutman D.; Bruno A.M.; Briggs C.A.; James B.D.; Stutzmann G.E.; Bennett D.A.; Miller S.A.; Rigo F.; Marr R.A.; Hastings M.L.; Therapeutic correction of ApoER2 splicing in Alzheimer\u2019s disease mice using antisense oligonucleotides. EMBO Mol Med 2016,8(4),328-345","journal-title":"EMBO Mol Med"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3233\/JAD-131883","volume":"40","author":"Farr S.A.","year":"2014","unstructured":"Farr S.A.; Erickson M.A.; Niehoff M.L.; Banks W.A.; Morley J.E.; Central and peripheral administration of antisense oligonucleotide targeting amyloid-\u03b2 protein precursor improves learning and memory and reduces neuroinflammatory cytokines in Tg2576 (A\u03b2PPswe) mice. J Alzheimers Dis 2014,40(4),1005-1016","journal-title":"J Alzheimers Dis"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3233\/JAD-2011-111517","volume":"28","author":"Erickson M.A.","year":"2012","unstructured":"Erickson M.A.; Niehoff M.L.; Farr S.A.; Morley J.E.; Dillman L.A.; Lynch K.M.; Banks W.A.; Peripheral administration of antisense oligonucleotides targeting the amyloid-\u03b2 protein precursor reverses A\u03b2PP and LRP-1 overexpression in the aged SAMP8 mouse brain. J Alzheimers Dis 2012,28(4),951-960","journal-title":"J Alzheimers Dis"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.bbi.2012.07.119","volume":"26","author":"Erickson M.A.","year":"2012","unstructured":"Erickson M.A.; Farr S.A.; Niehoff M.L.; Morley J.E.; Banks W.A.; 95. Antisense directed against the amyloid precursor protein reduces cytokine expression in the brain and improves learning and memory in the Tg2576 mouse model of alzheimer\u2019s disease. Brain Behav Immun 2012,26,S27","journal-title":"Brain Behav Immun"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2013.06.017","volume":"65","author":"Fiorini A.","year":"2013","unstructured":"Fiorini A.; Sultana R.; F\u00f6rster S.; Perluigi M.; Cenini G.; Cini C.; Cai J.; Klein J.B.; Farr S.A.; Niehoff M.L.; Morley J.E.; Kumar V.B.; Butterfield D.A.; Antisense directed against PS-1 gene decreases brain oxidative markers in aged senescence accelerated mice (SAMP8) and reverses learning and memory impairment: a proteomics study. Free Radic Biol Med 2013,65,1-14","journal-title":"Free Radic Biol Med"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.freeradbiomed.2013.11.014","volume":"67","author":"Farr S.A.","year":"2014","unstructured":"Farr S.A.; Ripley J.L.; Sultana R.; Zhang Z.; Niehoff M.L.; Platt T.L.; Murphy M.P.; Morley J.E.; Kumar V.; Butterfield D.A.; Antisense oligonucleotide against GSK-3\u03b2 in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease. Free Radic Biol Med 2014,67,387-395","journal-title":"Free Radic Biol Med"},{"key":"ref=101","first-page":"117","volume":"7","author":"Chen S.","year":"2013","unstructured":"Chen S.; Ge X.; Chen Y.; Lv N.; Liu Z.; Yuan W.; Advances with RNA interference in Alzheimer\u2019s disease research. Drug Des Devel Ther 2013,7,117-125","journal-title":"Drug Des Devel Ther"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-pharmtox-010715-103633","volume":"56","author":"Bobbin M.L.","year":"2016","unstructured":"Bobbin M.L.; Rossi J.J.; RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise? Annu Rev Pharmacol Toxicol 2016,56,103-122","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"36","DOI":"10.55782\/ane-2015-2014","volume":"75","author":"Sierant M.","year":"2015","unstructured":"Sierant M.; Piotrzkowska D.; Nawrot B.; RNAi mediated silencing of cyclin-dependent kinases of G1 phase slows down the cell-cycle progression and reduces apoptosis. Acta Neurobiol Exp (Warsz) 2015,75(1),36-47","journal-title":"Acta Neurobiol Exp (Warsz)"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"961","DOI":"10.2174\/1567205011666141107150938","volume":"11","author":"Zhang Q.","year":"2014","unstructured":"Zhang Q.; Li N.; Jiao X.; Qin X.; Kaur R.; Lu X.; Song J.; Wang L.; Wang J.; Niu Q.; Caspase-3 short hairpin RNAs: a potential therapeutic agent in neurodegeneration of aluminum-exposed animal model. Curr Alzheimer Res 2014,11(10),961-970","journal-title":"Curr Alzheimer Res"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1038\/mt.2013.189","volume":"21","author":"Liu G.P.","year":"2013","unstructured":"Liu G.P.; Wei W.; Zhou X.; Shi H.R.; Liu X.H.; Chai G.S.; Yao X.Q.; Zhang J.Y.; Peng C.X.; Hu J.; Li X.C.; Wang Q.; Wang J.Z.; Silencing PP2A inhibitor by lenti-shRNA interference ameliorates neuropathologies and memory deficits in tg2576 mice. Mol Ther 2013,21(12),2247-2257","journal-title":"Mol Ther"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/mt.2013.118","volume":"21","author":"Murphy S.R.","year":"2013","unstructured":"Murphy S.R.; Chang C.C.Y.; Dogbevia G.; Bryleva E.Y.; Bowen Z.; Hasan M.T.; Chang T.Y.; Acat1 knockdown gene therapy decreases amyloid-\u03b2 in a mouse model of Alzheimer\u2019s disease. Mol Ther 2013,21(8),1497-1506","journal-title":"Mol Ther"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.12659\/MSM.891219","volume":"20","author":"Jab\u0142kowski M.","year":"2014","unstructured":"Jab\u0142kowski M.; Szemraj M.; Oszajca K.; Janiszewska G.; Bartkowiak J.; Szemraj J.; New type of BACE1 siRNA delivery to cells. Med Sci Monit 2014,20,2598-2606","journal-title":"Med Sci Monit"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/978-1-60761-533-0_15","volume":"614","author":"Peng K.A.","year":"2010","unstructured":"Peng K.A.; Masliah E.; Lentivirus-expressed siRNA vectors against Alzheimer disease. Methods Mol Biol 2010,614,215-224","journal-title":"Methods Mol Biol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1021\/bm401906p","volume":"15","author":"Gao Y.","year":"2014","unstructured":"Gao Y.; Wang Z.Y.; Zhang J.; Zhang Y.; Huo H.; Wang T.; Jiang T.; Wang S.; RVG-peptide-linked trimethylated chitosan for delivery of siRNA to the brain. Biomacromolecules 2014,15(3),1010-1018","journal-title":"Biomacromolecules"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3233\/JAD-142919","volume":"45","author":"Lee D.Y.","year":"2015","unstructured":"Lee D.Y.; Moon J.; Lee S.T.; Jung K.H.; Park D.K.; Yoo J.S.; Sunwoo J.S.; Byun J.I.; Shin J.W.; Jeon D.; Jung K.Y.; Kim M.; Lee S.K.; Chu K.; Distinct expression of long non-coding rnas in an alzheimer\u2019s disease model. J Alzheimers Dis 2015,45(3),837-849","journal-title":"J Alzheimers Dis"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1172\/JCI78421","volume":"125","author":"Santa-Maria I.","year":"2015","unstructured":"Santa-Maria I.; Alaniz M.E.; Renwick N.; Cela C.; Fulga T.A.; Van Vactor D.; Tuschl T.; Clark L.N.; Shelanski M.L.; McCabe B.D.; Crary J.F.; Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau. J Clin Invest 2015,125(2),681-686","journal-title":"J Clin Invest"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"19946","DOI":"10.1038\/srep19946","volume":"6","author":"Pereira P.A.","year":"2016","unstructured":"Pereira P.A.; Tom\u00e1s J.F.; Queiroz J.A.; Figueiras A.R.; Sousa F.; Recombinant pre-miR-29b for Alzheimer\u2019s disease therapeutics. Sci Rep 2016,6,19946","journal-title":"Sci Rep"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.brainresbull.2012.05.018","volume":"88","author":"Zhu H.C.","year":"2012","unstructured":"Zhu H.C.; Wang L.M.; Wang M.; Song B.; Tan S.; Teng J.F.; Duan D.X.; MicroRNA-195 downregulates Alzheimer\u2019s disease amyloid-\u03b2 production by targeting BACE1. Brain Res Bull 2012,88(6),596-601","journal-title":"Brain Res Bull"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.neuro.2016.07.004","volume":"56","author":"Zhang Y.","year":"2016","unstructured":"Zhang Y.; Li Q.; Liu C.; Gao S.; Ping H.; Wang J.; Wang P.; MiR-214-3p attenuates cognition defects via the inhibition of autophagy in SAMP8 mouse model of sporadic Alzheimer\u2019s disease. Neurotoxicology 2016,56,139-149","journal-title":"Neurotoxicology"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"24566","DOI":"10.1038\/srep24566","volume":"6","author":"Zhang Y.","year":"2016","unstructured":"Zhang Y.; Liu C.; Wang J.; Li Q.; Ping H.; Gao S.; Wang P.; MiR-299-5p regulates apoptosis through autophagy in neurons and ameliorates cognitive capacity in APPswe\/PS1dE9 mice. Sci Rep 2016,6,24566","journal-title":"Sci Rep"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1096\/fj.201601308","volume":"31","author":"Salta E.","year":"2017","unstructured":"Salta E.; De Strooper B.; microRNA-132: A key noncoding RNA operating in the cellular phase of Alzheimer\u2019s disease. FASEB J 2017,31(2),424-433","journal-title":"FASEB J"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1261\/rna.044008.113","volume":"20","author":"Roshan R.","year":"2014","unstructured":"Roshan R.; Shridhar S.; Sarangdhar M.A.; Banik A.; Chawla M.; Garg M.; Singh V.P.; Pillai B.; Brain-specific knockdown of miR-29 results in neuronal cell death and ataxia in mice. RNA 2014,20(8),1287-1297","journal-title":"RNA"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"14717","DOI":"10.1523\/JNEUROSCI.2053-15.2015","volume":"35","author":"Kim J.","year":"2015","unstructured":"Kim J.; Yoon H.; Horie T.; Burchett J.M.; Restivo J.L.; Rotllan N.; Ram\u00edrez C.M.; Verghese P.B.; Ihara M.; Hoe H.S.; Esau C.; Fern\u00e1ndez-Hernando C.; Holtzman D.M.; Cirrito J.R.; Ono K.; Kim J.; microRNA-33 Regulates ApoE lipidation and amyloid-\u03b2 metabolism in the brain. J Neurosci 2015,35(44),14717-14726","journal-title":"J Neurosci"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1248\/bpb.b16-00898","volume":"40","author":"Wang C.N.","year":"2017","unstructured":"Wang C.N.; Wang Y.J.; Wang H.; Song L.; Chen Y.; Wang J.L.; Ye Y.; Jiang B.; The Anti-dementia effects of donepezil involve miR-206-3p in the hippocampus and cortex. Biol Pharm Bull 2017,40(4),465-472","journal-title":"Biol Pharm Bull"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.mehy.2011.11.019","volume":"78","author":"Wang L.L.","year":"2012","unstructured":"Wang L.L.; Huang Y.; Wang G.; Chen S.D.; The potential role of microRNA-146 in Alzheimer\u2019s disease: Biomarker or therapeutic target? Med Hypotheses 2012,78(3),398-401","journal-title":"Med Hypotheses"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000430356","volume":"37","author":"Liu Z.","year":"2015","unstructured":"Liu Z.; Wang C.; Wang X.; Xu S.; Therapeutic Effects of Transplantation of As-MiR-937-Expressing mesenchymal stem cells in murine model of alzheimer\u2019s disease. Cell Physiol Biochem 2015,37(1),321-330","journal-title":"Cell Physiol Biochem"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.pneurobio.2016.11.001","volume":"155","author":"Gustincich S.","year":"2017","unstructured":"Gustincich S.; Zucchelli S.; Mallamaci A.; The Yin and Yang of nucleic acid-based therapy in the brain. Prog Neurobiol 2017,155,194-211","journal-title":"Prog Neurobiol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/WNR.0b013e32835542b0","volume":"23","author":"Lukiw W.J.","year":"2012","unstructured":"Lukiw W.J.; Alexandrov P.N.; Zhao Y.; Hill J.M.; Bhattacharjee S.; Spreading of Alzheimer\u2019s disease inflammatory signaling through soluble micro-RNA. Neuroreport 2012,23(10),621-626","journal-title":"Neuroreport"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/ana.23588","volume":"72","author":"Lee S.T.","year":"2012","unstructured":"Lee S.T.; Chu K.; Jung K.H.; Kim J.H.; Huh J.Y.; Yoon H.; Park D.K.; Lim J.Y.; Kim J.M.; Jeon D.; Ryu H.; Lee S.K.; Kim M.; Roh J.K.; miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Ann Neurol 2012,72(2),269-277","journal-title":"Ann Neurol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.omtn.2018.03.007","volume":"11","author":"Gy\u00f6rgy B.","year":"2018","unstructured":"Gy\u00f6rgy B.; L\u00f6v C.; Zaborowski M.P.; Takeda S.; Kleinstiver B.P.; Commins C.; Kastanenka K.; Mu D.; Volak A.; Giedraitis V.; Lannfelt L.; Maguire C.A.; Joung J.K.; Hyman B.T.; Breakefield X.O.; Ingelsson M.; Crispr\/Cas9 mediated disruption of the swedish app allele as a therapeutic approach for early-onset Alzheimer\u2019s disease. Mol Ther Nucleic Acids 2018,11,429-440","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2174\/156652311798192833","volume":"11","author":"Shimamura M.","year":"2011","unstructured":"Shimamura M.; Sato N.; Morishita R.; Experimental and clinical application of plasmid DNA in the field of central nervous diseases. Curr Gene Ther 2011,11(6),491-500","journal-title":"Curr Gene Ther"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1001\/jamaneurol.2015.1807","volume":"72","author":"Tuszynski M.H.","year":"2015","unstructured":"Tuszynski M.H.; Yang J.H.; Barba D.; U, H.S.; Bakay, R.A.E.; Pay, M.M.; Masliah, E.; Conner, J.M.; Kobalka, P.; Roy, S.; Nagahara, A.H. Nerve growth factor gene therapy: Activation of neuronal responses in Alzheimer disease. JAMA Neurol 2015,72(10),1139-1147","journal-title":"JAMA Neurol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/gt.2015.81","volume":"23","author":"Ren J.","year":"2016","unstructured":"Ren J.; Chen Y.I.; Liu C.H.; Chen P.C.; Prentice H.; Wu J.Y.; Liu P.K.; Noninvasive tracking of gene transcript and neuroprotection after gene therapy. Gene Ther 2016,23(1),1-9","journal-title":"Gene Ther"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/jgm.1633","volume":"14","author":"Li Y.","year":"2012","unstructured":"Li Y.; Wang J.; Grebogi C.; Foote M.; Liu F.; A syringe-focused ultrasound device for simultaneous injection of DNA and gene transfer. J Gene Med 2012,14(1),54-61","journal-title":"J Gene Med"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jalz.2013.09.004","volume":"10","author":"Rafii M.S.","year":"2014","unstructured":"Rafii M.S.; Baumann T.L.; Bakay R.A.E.; Ostrove J.M.; Siffert J.; Fleisher A.S.; Herzog C.D.; Barba D.; Pay M.; Salmon D.P.; Chu Y.; Kordower J.H.; Bishop K.; Keator D.; Potkin S.; Bartus R.T.A.; A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer\u2019s disease. Alzheimers Dement 2014,10(5),571-581","journal-title":"Alzheimers Dement"},{"key":"ref=131","first-page":"240","volume":"12","author":"Mandel R.J.","year":"2010","unstructured":"Mandel R.J.; CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer\u2019s disease. Curr Opin Mol Ther 2010,12(2),240-247","journal-title":"Curr Opin Mol Ther"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2018.0233","volume":"75","author":"Rafii M.S.","year":"2018","unstructured":"Rafii M.S.; Tuszynski M.H.; Thomas R.G.; Barba D.; Brewer J.B.; Rissman R.A.; Siffert J.; Aisen P.S.; Mintzer J.; Lerner A.; Levey A.; Burke J.; Sano M.; Turner S.; Zamrini E.; Grill J.; Marson D.; AAV2-NGF Study Team. Adeno-Associated viral Vector (Serotype 2)-Nerve growth factor for patients with alzheimer disease: A randomized clinical trial. JAMA Neurol 2018,75(7),834-841","journal-title":"JAMA Neurol"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.neurobiolaging.2016.04.020","volume":"44","author":"Zhao L.","year":"2016","unstructured":"Zhao L.; Gottesdiener A.J.; Parmar M.; Li M.; Kaminsky S.M.; Chiuchiolo M.J.; Sondhi D.; Sullivan P.M.; Holtzman D.M.; Crystal R.G.; Paul S.M.; Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer\u2019s disease mouse models. Neurobiol Aging 2016,44,159-172","journal-title":"Neurobiol Aging"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/jnr.22603","volume":"89","author":"Sutcliffe J.G.","year":"2011","unstructured":"Sutcliffe J.G.; Hedlund P.B.; Thomas E.A.; Bloom F.E.; Hilbush B.S.; Peripheral reduction of \u03b2-amyloid is sufficient to reduce brain \u03b2-amyloid: implications for Alzheimer\u2019s disease. J Neurosci Res 2011,89(6),808-814","journal-title":"J Neurosci Res"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"12292","DOI":"10.1073\/pnas.1606171113","volume":"113","author":"Katsouri L.","year":"2016","unstructured":"Katsouri L.; Lim Y.M.; Blondrath K.; Eleftheriadou I.; Lombardero L.; Birch A.M.; Mirzaei N.; Irvine E.E.; Mazarakis N.D.; Sastre M.; PPAR\u03b3-coactivator-1\u03b1 gene transfer reduces neuronal loss and amyloid-\u03b2 generation by reducing \u03b2-secretase in an Alzheimer\u2019s disease model. Proc Natl Acad Sci USA 2016,113(43),12292-12297","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00018-016-2345-4","volume":"74","author":"Qu J.","year":"2017","unstructured":"Qu J.; Yu S.; Zheng Y.; Zheng Y.; Yang H.; Zhang J.; Aptamer and its applications in neurodegenerative diseases. Cell Mol Life Sci 2017,74(4),683-695","journal-title":"Cell Mol Life Sci"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1089\/nat.2014.0492","volume":"24","author":"McConnell E.M.","year":"2014","unstructured":"McConnell E.M.; Holahan M.R.; DeRosa M.C.; Aptamers as promising molecular recognition elements for diagnostics and therapeutics in the central nervous system. Nucleic Acid Ther 2014,24(6),388-404","journal-title":"Nucleic Acid Ther"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"442","DOI":"10.2174\/1567205011310040009","volume":"10","author":"Tannenberg R.K.","year":"2013","unstructured":"Tannenberg R.K.; Shamaileh H.A.; Lauridsen L.H.; Kanwar J.R.; Dodd P.R.; Veedu R.N.; Nucleic acid aptamers as novel class of therapeutics to mitigate Alzheimer\u2019s disease pathology. Curr Alzheimer Res 2013,10(4),442-448","journal-title":"Curr Alzheimer Res"},{"key":"ref=139","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/697923","volume":"2014","author":"Ashrafuzzaman M.","year":"2014","unstructured":"Ashrafuzzaman M.; Aptamers as both drugs and drug-carriers. Biomed Res Int 2014,2014","journal-title":"Biomed Res Int"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10719-016-9682-2","volume":"33","author":"Yamagishi S.","year":"2016","unstructured":"Yamagishi S.; Taguchi K.; Fukami K.; DNA-aptamers raised against AGEs as a blocker of various aging-related disorders. Glycoconj J 2016,33(4),683-690","journal-title":"Glycoconj J"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12668-012-0040-y","volume":"2","author":"Mathew A.","year":"2012","unstructured":"Mathew A.; Aravind A.; Brahatheeswaran D.; Fukuda T.; Nagaoka Y.; Hasumura T.; Iwai S.; Morimoto H.; Yoshida Y.; Maekawa T.; Venugopal K.; Sakthi Kumar D.; Amyloid-Binding Aptamer Conjugated Curcumin-PLGA Nanoparticle for Potential Use in Alzheimer\u2019s Disease. Bionanoscience 2012,2,83-93","journal-title":"Bionanoscience"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1039\/C8CC02256A","volume":"54","author":"Chakravarthy M.","year":"2018","unstructured":"Chakravarthy M.; AlShamaileh H.; Huang H.; Tannenberg R.K.; Chen S.; Worrall S.; Dodd P.R.; Veedu R.N.; Development of DNA aptamers targeting low-molecular-weight amyloid-\u03b2 peptide aggregates in vitro. Chem Commun (Camb) 2018,54(36),4593-4596","journal-title":"Chem Commun (Camb)"},{"key":"ref=143","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140733","volume":"10","author":"Liang H.","year":"2015","unstructured":"Liang H.; Shi Y.; Kou Z.; Peng Y.; Chen W.; Li X.; Li S.; Wang Y.; Wang F.; Zhang X.; Inhibition of BACE1 activity by a DNA Aptamer in an alzheimer\u2019s disease cell model. PLoS One 2015,10(10)","journal-title":"PLoS One"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.omtn.2019.02.025","volume":"16","author":"Xiang J.","year":"2019","unstructured":"Xiang J.; Zhang W.; Cai X.F.; Cai M.; Yu Z.H.; Yang F.; Zhu W.; Li X.T.; Wu T.; Zhang J.S.; Cai D.F.; DNA Aptamers Targeting BACE1 reduce amyloid levels and rescue neuronal deficiency in cultured cells. Mol Ther Nucleic Acids 2019,16,302-312","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3390\/ijms20020299","volume":"20","author":"Janas T.","year":"2019","unstructured":"Janas T.; Sapo\u0144 K.; Stowell M.H.B.; Janas T.; Selection of Membrane RNA Aptamers to Amyloid Beta Peptide: Implications for exosome-based antioxidant strategies. Int J Mol Sci 2019,20(2),299","journal-title":"Int J Mol Sci"},{"key":"ref=146","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089901","volume":"9","author":"Farrar C.T.","year":"2014","unstructured":"Farrar C.T.; William C.M.; Hudry E.; Hashimoto T.; Hyman B.T.; RNA aptamer probes as optical imaging agents for the detection of amyloid plaques. PLoS One 2014,9(2)","journal-title":"PLoS One"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.talanta.2014.11.020","volume":"134","author":"Babu E.","year":"2015","unstructured":"Babu E.; Muthu Mareeswaran P.; Sathish V.; Singaravadivel S.; Rajagopal S.; Sensing and inhibition of amyloid-\u03b2 based on the simple luminescent aptamer-ruthenium complex system. Talanta 2015,134,348-353","journal-title":"Talanta"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1021\/acs.molpharmaceut.6b00165","volume":"13","author":"Kim J.H.","year":"2016","unstructured":"Kim J.H.; Kim E.; Choi W.H.; Lee J.; Lee J.H.; Lee H.; Kim D.E.; Suh Y.H.; Lee M.J.; Inhibitory RNA aptamers of tau oligomerization and their neuroprotective roles against proteotoxic stress. Mol Pharm 2016,13(6),2039-2048","journal-title":"Mol Pharm"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"7793","DOI":"10.1021\/acs.analchem.6b01825","volume":"88","author":"Kim S.","year":"2016","unstructured":"Kim S.; Wark A.W.; Lee H.J.; Femtomolar detection of tau proteins in undiluted plasma using surface plasmon resonance. Anal Chem 2016,88(15),7793-7799","journal-title":"Anal Chem"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1039\/C8AN00527C","volume":"143","author":"Shui B.","year":"2018","unstructured":"Shui B.; Tao D.; Cheng J.; Mei Y.; Jaffrezic-Renault N.; Guo Z.; A novel electrochemical aptamer-antibody sandwich assay for the detection of tau-381 in human serum. Analyst (Lond) 2018,143(15),3549-3554","journal-title":"Analyst (Lond)"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"10757","DOI":"10.1038\/srep10757","volume":"5","author":"Lee J.H.","year":"2015","unstructured":"Lee J.H.; Shin S.K.; Jiang Y.; Choi W.H.; Hong C.; Kim D.E.; Lee M.J.; Facilitated tau degradation by usp14 aptamers via enhanced proteasome activity. Sci Rep 2015,5,10757","journal-title":"Sci Rep"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/181925","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/181925\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/181925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T19:53:45Z","timestamp":1722887625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/181925\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,16]]},"references-count":151,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2020,10,16]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557520666200513122357","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,16]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-11-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}